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Background: The data from randomised trials suggested that primary tumour sidedness could represent a prognostic and predictive
factor in colorectal cancer (CRC) patients, particularly during treatment with anti-epidermal growth factor receptor (EGFR) therapy.
However, an in-deep molecular selection might overcome the predictive role of primary tumour location in this setting.
Methods: We conducted a retrospective analysis in which tumour samples from RAS/BRAF wild-type (WT) metastatic CRC
patients treated with second-third-line irinotecan/cetuximab were analysed for EGFR gene copy number (GCN) and promoter
methylation. Study objective was to evaluate the correlation of tumour sidedness, EGFR promoter methylation and EGFR GCN
with clinical outcome. Median follow-up duration was 14.3 months.
Results: Eighty-eight patients were included in the study, 27.3% had right-sided CRC, 72.7% had left-sided CRC; 36.4% had EGFR
GCNo2.12 tumour, 63.6% had EGFR GCNX2.12 tumour; 50% had EGFR promoter-methylated tumour. Right-sided colorectal
cancer (RSCRC) were associated with reduced overall response rate (ORR) (4.2% for RSCRC vs 35.9% for left sided colorectal
cancer (LSCRC), P¼ 0.0030), shorter progression-free survival (PFS) (3.0 vs 6.75 months, Po0.0001) and shorter overall survival (OS)
(8 vs 13.6 months, Po0.0001). EGFR GCNo2.12 tumours were associated with reduced ORR (6.2% for EGFR GCNo2.12 vs 39.3%
for EGFR GCNX2.12 tumours, P¼ 0.0009), shorter PFS (3.5 vs 6.5 months, P¼ 0.0006) and shorter OS (8.5 vs 14.0 months,
Po0.0001). Epidermal growth factor receptor-methylated tumours were associated with reduced ORR (9.1% for methylated vs
45.5% for unmethylated, P¼ 0.0001), shorter PFS (3 vs 7.67 months, Po0.0001) and shorter OS (8 vs 17 months, Po0.0001). At
multivariate analysis, EGFR GCN and EGFR promoter methylation maintained their independent role for ORR (respectively
P¼ 0.0082 and 0.0025), PFS (respectively P¼ 0.0048 ando0.0001) and OS (respectively P¼ 0.0001 ando0.0001).
Conclusions: In our study, an accurate molecular selection based on an all RAS and BRAF analysis along with EGFR GCN and
EGFR promoter methylation status seems to be more relevant than primary tumour sidedness in the prediction of clinical outcome
during cetuximab/irinotecan therapy. However, these data need to be validated with future prospective and translational studies.
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Although the global therapeutic strategy has considerably
improved in the past few years, colorectal cancer (CRC) still
represents a leading cause of death worldwide (Ferlay et al, 2013,
2014). The fast-growing knowledge of molecular mechanisms
underlying colorectal tumours led in fact to a corresponding
development of effective molecular targeted treatments able to
significantly improve clinical outcome for patients presenting with
metastatic disease from the original 6–10 months median survival
to the current 30 months and more (Van Cutsem et al, 2016).
We now know that metastatic CRC is a biologically hetero-
geneous disease and primary tumours originating from different
areas of the colon have critical molecular differences that have been
suggested to translate into just as many critical differences under
the clinical point of view. In particular, different data sets indicated
that right-sided colorectal cancers (RSCRC) patients experienced a
worse clinical outcome than left-sided colorectal cancer (LSCRC)
patients with otherwise comparable clinical characteristics
(Loupakis et al, 2015; Moretto et al, 2016; Tejpar et al, 2016;
Venook et al, 2016).
Interestingly, findings from subset analyses of phase 3 trials
also indicated a possible lack of efficacy for the use of
anti-epidermal growth factor receptor (EGFR) monoclonal anti-
bodies (that is, cetuximab and panitumumab) in metastatic
colorectal cancer patients with RAS wild-type (WT) RSCRC. On
the contrary, RAS WT LSCRC patients apparently showed to
derive an increasingly significant clinical benefit from such a
treatment approach. Taken together, these observations implied
that along with a well-established prognostic role, primary tumour
location could also represent a relevant predictive factor in
colorectal cancer patients receiving treatment directed against the
EGFR.
The molecular pathways leading to left- and right-sided primary
CRC are sensibly different and could ultimately explain the distinct
biological and clinical traits of these tumours.
Right-sided colorectal cancer are more often hyper-mutated,
present microsatellite instability and CpG-islands methylation and
BRAF mutations. On the other hand, LSCRC have more likely
chromosomal instability, EGFR and HER2-neu amplifications,
epiregulin and amphiregulin (EREG and AREG) high gene
expression levels (Distler and Holt, 1997; Iacopetta, 2002;
Hutchins et al, 2011; Tran et al, 2011; Missiaglia et al, 2014;
Loupakis et al, 2015; Choi et al, 2016; Moretto et al, 2016; Tejpar
et al, 2016; Venook et al, 2016; Lee et al, 2016a). Patients with
tumors that have high gene expression levels of EREG and AREG,
are more likely to have disease control on cetuximab treatment
(Khambata-Ford et al, 2007).
Recently, Lee et al indicated that, in K-RAS wild-type metastatic
CRC patients receiving anti-EGFR therapy, the molecular char-
acteristics that are considered typical of RSCRC more frequently
overlapped with the consensus molecular subtypes (CMS) of
colorectal cancer type 1 (MSI immune), whereas CMS type 3 and 4
were recurrent in LSCRC (Guinney et al, 2015; Lee et al, 2016b).
The authors also found a correlation between the different
molecular characteristics investigated and survival results, thus
confirming a consistent link between molecular features and
clinical outcome. Overall, these findings suggested that besides
primary tumour location, the biological profile might be actually
more relevant in defining the clinical behaviour of colorectal
cancer.
We could then speculate that the more accurate the biological
selection is the less relevant primary tumour location would be in
the prediction of clinical outcome during treatment with mono-
clonal antibodies directed against the EGFR.
On this basis, we analysed the prognostic and predictive role of
CRC primary tumour location, EGFR GCN and EGFR promoter
methylation in RAS and BRAF wild-type mCRC patients treated
with second- third line cetuximab/irinotecan therapy.
PATIENTS AND METHODS
We retrospectively collected primary tumour samples from RAS/
BRAF WT metastatic CRC patients treated with second-third-line
irinotecan/cetuximab and analysed them for EGFR GCN and
promoter methylation.
Patients selection. Patients with histologically proven, RAS and
BRAF wild-type, metastatic colorectal cancer receiving a combina-
tion of cetuximab and irinotecan after at least one line of previous
chemotherapy were eligible for our analysis.
All patients received cetuximab at an initial dose of 400mgm 2
followed by weekly infusions of 250mgm 2. Irinotecan was
administered at a dose of 180mgm 2every 2 weeks, either alone
or in combination with 5-fluorouracil and leucovorin. So, they
received modified FOLFIRI (irinotecan 180mgm 2 d1, 5FU bolus
400mgm 2 d1, 5FU 2400mgm 2 continuous infusion for 46 h)
plus cetuximab or irinotecan plus cetuximab.
To be eligible, patients must also have previously received an
irinotecan-based chemotherapy regimen for at least 6 weeks and
must have presented progression of disease during receipt of this
regimen or within 3 months thereafter. All patients received first-
line chemotherapy (oxaliplatin-based or irinotecan-based) in
combination with bevacizumab. For patients receiving third-line
cetuximab, second-line treatment consisted of modified FOLFIRI
in all cases.
Tumour response was evaluated every 8 weeks by clinicians’
assessment and according to the Response Evaluation Criteria in
Solid Tumours (RECIST v1.1).
Median follow up duration was 14.3 months.
Epidermal growth factor receptor promoter methylation and
EGFR GCN were analysed on formalin-fixed and paraffin-
embedded tumour samples for all patients included. For study
purposes, right-sided and left-sided colorectal primary tumours
were defined as proximal or distal to the splenic flexure. This study
was approved by the Institutional Review Board.
Mutational analysis. Evaluation for RAS and B-raf status was
conducted for all patients included in the analysis by standard
pyrosequencing technique: all evaluations have been performed by
PyroMark Q96 ID system (Qiagen, Germany) or by Pyromark ID
system (Biotage AB, Sweden).
The kits ‘Anti-EGFR MoAb response’, respectively for K-ras,
N-ras and B-raf status, allow to identify the most common and
prevalent mutations of K-ras, N-ras and B-raf gene.
The kit for K-ras evaluates hot-spots mutations in codons 12,
13, 59, 61, 117 and 146 of K-ras gene (predominantly G12D, G12A,
G12V, G12S, G12R, G12C, G13D, A59T, Q61H, K117N, A146T).
The kit for N-ras evaluates hot-spots mutations in codons 12,
13, 59, 61, 117 and 146 of N-ras gene (predominantly G12S, G12D,
G13R, G13D, A59T, Q61K, Q61L, Q61R, K117N, A146T).
The kit for B-raf evaluates hot-spots mutations in codons 15 and
11 of B-raf gene (predominantly V600E, V600K, V600M, T599M,
K601E, G469V-A-E and G464V-E).
After tumour DNA extraction and amplification (through
Rotor-Gene Q, Qiagen, Germany), genotyping and allele frequen-
cing is determined by standard pyrosequencing technique: the
detection of bioluminescence caused by the nucleotide annealing to
the sequence and the relative intensity of the luminescence
produced is directly proportional to the number of annealed
nucleotides caused by the reaction of the DNA polymerase, that
starting from the primers used, do appear at the end of the
amplification.
Variant allele frequencies (VAF) for the different analyses, by
manufacturer’s description are as follows:
K-ras codon 12: 10%
K-ras codon 13: 8%
BRITISH JOURNAL OF CANCER Tumour sidedness and molecular characterisation
316 www.bjcancer.com |DOI:10.1038/bjc.2017.178
K-ras codon 59 pos1: A 12–15%, T 4–7%, C 8–12%
K-ras codon 61 pos3: C 7–10%, T 8–12%
K-ras codon 59 pos2: G 12–15%, T 4–7%, A12–15%
K-ras codon 61 pos2: C 12–15%, G 4–7%, T 4–7%
K-ras codon 61 pos 1: G 8–12%, A 4–7%
K-ras codon 117 pos3: G 12–15%, A8–12%
K-ras codon 117 pos1: G 8–12%, C 8–12%
K-ras codon 117 pos2: A 8–12%, C 8–12%, G 8–12%
K-ras codon 146 pos 1: G 8–12%, A 12–15%, T 8–12%
K-ras codon 146 pos 2: T 12–15%, A 12–15%, C 12–15%
N-ras codon 12 pos1: T 3–5%, A 5–7%, C 3–5%
N-ras codon 13 pos1: T 7–10%, A 4–6%, C 3–5%
N-ras codon 12 pos2: T 6–9%, A 6–8%, C 3–5%
N-ras codon 13 pos2: T 7–10%, A 4–6%, C 4–6%
N-ras codon 58 pos 1: G 3–5%, T 8–10%, C 3–5%
N-ras codon 59 pos 1: A 9–11%, T 3–5%, C 8–10%
N-ras codon 61 pos 1: A 4–7%, G 3–5%
N-ras codon 58 pos 2: T 8–10%
N-ras codon 59 pos 2: 3–5%
N-ras codon 61 pos 2: G 3–5%, T 8–10%, C 4–6%
N-ras codon 61 pos 3: T 4–6%, C 7–9%
N-ras codon 117 pos 1/3: 4–6%
N-ras codon 117 pos 2: 6–8%
N-ras codon 146 pos 1: 5–7%
N-ras codon 146 pos 2: 8–10%
B-raf codon 600: E 3–5% K 8–10% M 8–10%
B-raf codon 599: I 8–10%
B-raf codon 601: E 8–10%
B-raf exon 11 codon 469 and 464: 8–10%.
EGFR promoter methylation. CpG island methylation is an
epigenetic mechanism of gene silencing more frequently observed
in right- than left-sided tumors and the methylation of the EGFR
promoter may be responsible for the loss of EGFR expression.
Analysis of EGFR promoter methylation was performed
following a DNA extraction protocol from paraffin-embedded
tissue and a methylation-specific PCR (MSP) as previously
described (Scartozzi et al, 2011). Analysis of EGFR promoter
methylation was performed following a DNA extraction protocol
from paraffin-embedded tissue and a methylation-specific PCR
(MSP). The tumour samples were processed according to the
QIAamp DNA mini Tissue Protocol, using QIAamp DNA Mini
Kit (Qiagen GmbH, Hilden, Germany). Before PCR amplification,
the DNA extract was treated with sodium bisulphite as described in
the handbook of the ‘EpiTect Bisulfite Kit’ (Qiagen GmbH).
Bisulphite modification of DNA to convert all unmethylated
cytosines to uracil and then to thymidine during the subsequent
PCR step while leaving the methylated cytosines unaffected was
performed as described by Herman et al, 1996. For PCR
amplification, two sets of primers were designed from nt  130
to  300 (relative to ATG) in the 50-untranslated region of the
human EGFR promoter.
The primer sequences used were 50-TGTTTTGTTTTTTTGTG
TTTTGGTTTGTGT-30 (sense) and 50-CATCCAATCTAAACAA-
CAACAACCACCA-30 (antisense) for unmethylated DNA and 50-
50-TGTTTTTTCGCGTTTCGGTTCGCGC-30 (sense) and 50-C
GTCTAAACGACGACGACCGCCG-30(antisense) for methylated
DNA, both of which amplify B150 bp products (Nagothu et al,
2004). The PCR mixture contained B1Å PCR buffer, minus Mg;
0.2m dNTP mixture (each); 1.5m MgCl; 0.2 m primer mix (each);
1.0 unit platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA,
USA); and bisulphite-modified DNA (of 1 ng–2mg) in a final
volume of 50 ml. Controls without DNA were performed for each
set of PCRs. Each PCR product (30 ml) was directly visualised on
10% acrylamide gels. The gel was stained with ethidium bromide
and photographed under UV illumination. An enzymatically
methylated human male genomic DNA (CpGenome Universal
Methylated DNA CHEMICON International) was used as a
methylation-positive control for gene methylation studies and was
processed as above mentioned.
EGFR GCN. Epidermal growth factor receptor GCN study was
performed with CISH analysis (chromogenic in situ hybridisation)
performed according to manufacturer’s instructions (Zymed
Laboratories Inc., South San Francisco, CA, USA) as previously
described. The cutoff point with the highest sensitivity and
specificity for estimating CISH EGFR GCN was set at 2.12,
according to our previous findings.
We previously performed a receiver operating characteristics
(ROC) analysis based on mean CISH EGFR gene copy number
with response to cetuximab therapy as end point. In that model
sensitivity was 51.5% (95% CI: 33.6–69.2) and specificity was 100%
(95% CI: 69–100). AUC was 0.77, P¼ 0.002 (Scartozzi et al, 2009;
Scartozzi et al, 2012).
Statistical analysis. Statistical analysis was performed with the
MedCalc Statistical Software version 14.10.2 (MedCalc Software
bvba, Ostend, Belgium; http://www.medcalc.org; 2014).
The association between categorical variables was estimated by
Fisher exact test for categorical binomial variables or by w2 test for
all other instances. Survival probability over time was estimated by
the Kaplan–Meier method. Significant differences in the prob-
ability of survival between the strata were evaluated by log-rank
test. Cox’s multiple regression analysis was used to assess the role
of tumour sidedness, EGFR promoter methylation and EGFR GCN
as prognostic factors adjusted for those variables resulted
significant at univariate analysis. The Holm–Sidak correction18
was used to adjust the values for multiple comparisons. Other
tested variables included gender (male vs female), median age
(o 70 vsX70 years), ECOG performance status (0 vs X1),
previous lines for metastatic disease (1 vs 2).
For statistical analysis, overall survival (OS) was defined as the
time interval between the date of beginning of cetuximab/
irinotecan treatment and death or last follow-up visit for patients
who were lost at follow-up, whereas progression-free survival (PFS)
was defined as the interval between the date of beginning of
cetuximab/irinotecan treatment to death, first sign of clinical
progression or last follow-up visit for patients who were lost at
follow-up.
RESULTS
A total of eighty-eight RAS/BRAF wild type metastatic colorectal
cancer patients treated with second-third-line irinotecan/cetux-
imab therapy were included in our analysis. Twenty-four patients
(27%) had right sided colorectal cancer and 64 patients (73%) had
left-sided colorectal cancer. EGFR GCNo2.12 was present in 32
colorectal tumours (36%), whereas the remaining 56 (64%) had
EGFR GCNZ2.12. Forty-four patients (50%) showed EGFR gene
promoter methylated tumours. EGFR promoter methylation and
EGFR amplification are not mutually exclusive. Twenty-five
patients (28.4%) presented both parameters.
Overall clinical and pathological patients’ characteristics were
well balanced across different groups and are summarised in
Table 1.
In the whole-group median OS (mOS) was 10 months (95% CI:
9.0 to 13.6 months), median PFS (mPFS) was 4 months (95% CI
3.6 to 6.2) and overall response rate (ORR) was 27.3%.
RSCC vs LSCC. Right-sided colon cancer were associated with
reduced ORR (4.2% for RSCC vs 35.9% for LSCC, P¼ 0.003);
mPFS was 3 months (95% CI 2,9 to 3,5) for RSCC vs 6.75 months
(95% CI: 5.8 to 7.7) for LSCC (HR: 2.7, Po0.0001) (Figure 1A).
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RSCC patients also showd a dcreased OS: mOS was 8 months
(95% CI: 4.0 to 8.9) vs 13.6 months (95% CI: 10.0 to 17.5) for
RSCC vs LSCC (HR: 2.83, Po0.0001) (Figure 1B).
Epidermal growth factor receptor gene promoter methylation was
more frequent in RSCC vs LSCC (respectively 95.8% vs 32.8%,
Po0.0001). On the contrary EGFR GCNZ2.12 was less frequently
observed in RSCRC vs LSCRC (respectively 16.7% vs 81.2%,
Po0.0001).
EGFR GCN. Epidermal growth factor receptor GCNo2.12 was
associated with a reduced ORR (6.2% for patients showing EGFR
GCNo2.12 vs 39.3% for those showing EGFR GCNX2.12,
P¼ 0.0009) asnd with a shorter PFS and OS. PFS was 3.5 months
(95% CI: 3.0 to 4.5) vs 6.5 months (95% CI: 3.9 to 8.0) HR: 1.98,
P¼ 0.0006 (Figure 2A) in patients with colorectal tumours
showing EGFR GCN respectivelyo2.12 orX2.12. Overall survival
was 8.5 months (95%CI: 6.0–9.8) vs 14 months (95% CI: 11.0–18.0)
for patients with colorectal tumours showing EGFR GCNo2.12 vs
EGFR GCNX2.12 (HR: 2.59, Po0.0001) (Figure 2B).
EGFR methylation. Patients with EGFR-methylated tumours vs
those with unmethylated tumours showed a reduced ORR (9.1%
for methylated vs 45.5% for unmethylated tumours, P¼ 0.0001).
Median PFS was 3 months (95% CI: 2.5 to 3.2) vs 7.67 months
(95% CI: 6.9 to 8.1), HR: 3.23, Po0.0001 (Figure 3A), and mOS
was 8 months (95% CI: 4.0 to 8.9) vs 17 months (95% CI: 13.6–
19.0) for patients with methylated vs unmethylated colorectal
tumours, respectively (HR: 3.57, Po0.0001) (Figure 3B). All results
have been also summarised in Table 2.
EGFR GCN Z2.12 and EGFR unmethylated tumours. Among
patients with EGFR GCN X2.12 tumours, those with unmethylated
tumours had a better survival: mOS was 18 months (95% CI: 17–
19.5) for unmethylated vs 8.4 (95% CI: 6—9.8) for methylated
tumours, HR 0.27, Po0.0001; mPFS was 8 months for unmethylated
(95% CI: 7.6–9) vs 2.9 months for methylated tumours (95% CI: 2.0
to 4.0), HR: 0.31, Po0.0001. They showed also better ORR: it was
58% for unmethylated vs 16% for methylated tumours, P¼ 0.001.
Multivariate analysis. At multivariate analysis, EGFR GCN and
EGFR promoter methylation maintained their independent role for
ORR (respectively P¼ 0.0082 and P¼ 0.0025), PFS (respectively
Exp(b): 0.408, 95% CI: 0.2–0.8, P¼ 0.0048 and Exp(b): 4.52, 95%
CI: 2.5–8.1, Po0.0001) and OS (respectively Exp(b): 0.23, 95% CI:
0.1–0.5, P¼ 0.0001 and Exp(b): 5.58. 95% CI: 2.8–11.1, Po0.0001).
On the contrary, tumour sidedness had not an independent role
for median OS (Exp(b): 0.58, 95% CI: 0.2–1.3, P¼ 0.20), PFS
(Exp(b): 0.817, 95% CI: 0.4–1.7, P¼ 0.60) or ORR (P¼ 0.95).
CONCLUSION
When it was first proposed the suggestion that primary tumour
location might represent a predictive factor for clinical outcome in
metastatic CRC patients seemed bound to redefine the therapeutic
strategy for these patients. This appeared particularly relevant for
anti-EGFR therapy, which demonstrated an impressive activity
profile in left-sided primary colorectal tumours and a substantial
lack of efficacy in right-sided primary tumours even in presence of
an all RAS wild-type mutational status. Nonetheless retrospective
observations also suggested that primary tumour sidedness might
just represent a surrogate factor substituting in fact for a
comprehensive molecular characterisation (Lee et al, 2016b;
Tejpar et al, 2016; Venook et al, 2016).
Our analysis confirmed that in RAS/BRAF wild-type colorectal
cancer patients, primary tumour location correlated with clinical
outcome during irinotecan/cetuximab treatment. Response rate,
PFS and OS were in fact reduced in right-sided vs left sided
tumours thus indicating that tumour sidedness should be
considered among key decision factors in this setting.
As previously observed by other authors and our group, we also
confirmed that EGFR GCN and EGFR gene promoter methylation
were significantly able to influence clinical outcome in terms of ORR,
PFS and OS in these patients (Moroni et al, 2005; Shia et al, 2005;
Sartore-Bianchi et al, 2007; Sholl et al, 2007; Cappuzzo et al, 2008;
Scartozzi et al, 2009; Scartozzi et al, 2011; Scartozzi et al, 2012). Even
more interestingly at multivariate analysis, only EGFR GCN and
EGFR gene promoter methylation maintained a significant role in
determining clinical results, while primary tumour location failed to
independently correlate with ORR, PFS or OS. Our data seemed then
to suggest that a thorough knowledge of molecular, genetic and epi-
genetic tumour characteristics, such as those that we investigated in
our study, might overcome the relevance of primary tumour location
as a predictive factor during anti-EGFR therapy.
In accordance with our findings, Lee et al showed that on the
one hand RSCC was associated with inferior OS and PFS but on
the other hand primary tumour sidedness was not a significant
factor at multivariate analysis in 198 K-RAS wild-type metastatic
Table 1. Patients characteristics in the whole group and according to primary tumour sidedness, EGFR gene copy number and
EGFR gene promoter methylation
Tumour sidedness EGFR GCN EGFR promoter methylation
Whole group Left Right X 2.12 o 2.12 Present Absent
88 64 (73%) 24 (27%) 56 (64%) 32 (36%) 44 (50%) 44 (50%)
Sex
Male 55 (63%) 47 (74%) 8 (33%) 35 (62%) 20 (62%) 28 (64) 27 (61%)
Female 33 (37%) 17 (26%) 16 (67%) 21 (38%) 12 (38%) 16 (36%) 17 (39%)
Age (range) 64 (34–81) 64 (34–81) 63 (33–79) 64 (33–81) 64 (34–78) 64 (34–81) 63 (33–78)
ECOG PS
0–1 61 (69%) 45 (70%) 16 (67%) 38 (68%) 23 (72%) 30 (68%) 31 (70%)
2 27 (31%) 19 (30%) 8 (33%) 18 (32%) 9 (27%) 14 (32%) 13 (30%)
Previous lines for
metastatic disease
1 21 (24%) 15 (23%) 6 (25%) 14 (25%) 7 (22%) 11 (25%) 10 (23%)
X 2 67 (76%) 49 (77%) 18 (75%) 42 (75%) 25 (78%) 33 (75%) 34 (77%)
Number of
metastatic sites
1 12 (14%) 9 (14%) 3 (13%) 8(14%) 4 (13%) 6 (14%) 6 (14%)
X 2 76 (86%) 55 (86%) 21(87) 48 (86%) 28 (87%) 38 (86%) 38 (86%)
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colorectal cancer patients receiving anti-EGFR treatment (Lee et al,
2016b). The Authors concluded that tumour biology could explain
better than primary tumour anatomical location, the different
clinical behaviour during therapy directed against the EGFR. RSCC
resulted in fact more frequently associated with BRAF mutations,
hypermethylation and a distinct gene expression pattern intrigu-
ingly overlapping with the CMS 1 (Guinney et al, 2015; Lee et al,
2016b). In accordance with these findings in our series, EGFR gene
promoter methylation was more frequently observed in right-sided
primary tumours, whereas EGFR GCNZ2.12 was more frequent
in left-sided primary tumours.
Unlike the study by Lee, the present analysis was not limited to
K-RAS but also included H-RAS and BRAF mutational status, thus
eliminating potential confounding factors linked to the beyond
K-RAS group of mutations with a known predictive and prognostic
role. In addition to a broader mutational spectrum, the patients’
population examined in our study was truly irinotecan-refractory.
Clinical results especially in terms of response rate and PFS were
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Figure 1. (A) Median progression-free survival (PFS) for patients with right sided (——) or left-sided (- - - -) primary colorectal tumours. Median
PFS was 3 vs 6.75 months for patients with right-sided vs left-sided tumours, respectively (HR: 2.74, 95% CI: 1.4–5.2, Po0.0001). (B)Median overall
survival (OS) for patients with right-sided (——) or left-sided (- - - -) primary colorectal tumours. Median OS was 8 vs13.6 months for patients with
right-sided vs left-sided tumours, respectively (HR: 2.83, 95% CI: 1.4–5.6, Po 0.0001).
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Figure 2. (A) Median progression-free survival (PFS) according to tumour EGFR GCNo2.12 (——) or tumour EGFR GCNZ2.12 (- - - -). Median
PFS for patients with tumour EGFR GCNo2.12 vs tumour EGFR GCNX2.12 was 3.5 months vs 6.5 months, respectively (HR: 1.98, 95% CI: 1.2–
3.3, P¼ 0.0006). (B)Median overall survival (OS) according to tumour EGFR GCNo2.12 (——) or tumour EGFR GCNX2.12 (- - - -). Median OS was
8.5 months vs 14 months for patients with tumour EGFR GCNo2.12 vs tumour EGFR GCNX2.12 tumour (HR: 2.59, 95% CI: 1.4–4.6, Po0.0001).
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Figure 3. (A) Median progression-free survival (PFS) for patients with EGFR promoter-methylated (- - - -) or EGFR promoter-unmethylated
colorectal tumours (——). Median PFS was 3 months vs 7.67 months for patients with EGFR promoter-methylated vs EGFR promoter-
unmethylated colorectal tumours, respectively (HR: 3.23, 95% CI: 2.0–5.3, Po0.0001). (B) Overall survival (OS) for patients with EGFR promoter-
methylated (- - - -) or EGFR promoter-unmethylated tumours (——). Median OS was 8 months vs 17 months for patients with EGFR promoter-
methylated vs EGFR promoter-unmethylated colorectal tumours, respectively (HR: 3.57, 95% CI: 2.1–6.1, Po0.0001).
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therefore mainly attributable to the activity of cetuximab rather
than to chemotherapy.
Unfortunately, although highly suggestive, several limitations
prevent from a straightforward application of our findings into the
clinical practice. This is in fact a retrospective study with a
relatively small sample size that should be mostly considered
hypothesis generating. Besides neither EGFR GCN nor EGFR gene
promoter methylation is broadly available and standardised.
As long as these observations and those from other authors are
not prospectively confirmed primary tumour location should remain
a valid surrogate for the molecular profile of colorectal cancer and it
should represent an important factor in the decision-making process
particularly when an anti-EGFR therapy is anticipated on the basis of
both RAS/BRAF mutational status and clinical indication. In patients
with RAS/BRAF wild-type LSCRC, chemotherapy in combination
with an anti-EGFR monoclonal antibody should then represent a
preferred option. Whereas in RAS/BRAF wild-type RSCRC che-
motherapy in combination with bevacizumab may be considered the
option of choice. Nonetheless, the use of anti-EGFR therapy as a
sequential alternative may still be relevant for RAS wild-type RSCRC
failing first-line.
In conclusion, it is mandatory to prospectively design sequence
trials that are stratified for side and at the same time conduct a
parallel translational study to define the role of EGFR GCN and
EGFR promoter methylation.
Further studies based also on the influence on outcome of
previous and subsequent lines of therapy are needed.
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